Categories
Health

How Pandemic Isolation Affected an Alzheimer’s Affected person in a Nursing Residence

While the nurses came to change Peggy’s bedding, I spoke to her nurse in the hallway. When Peggy arrived at this facility about two weeks earlier, she had pressure ulcers on her heels and lower back. In Peggy’s room, her nurse changed her bandages and pointed out the wounds on her heels, which didn’t look bad, but on her back, just above her tailbone, a plate the size of a plate was sore, yellowish, and raw. “It’s gotten so much better,” said the nurse, running her finger over a circle about a third larger than the one I could see.

Both pressure ulcers and pulmonary embolisms can be caused by lying in the same position for too long. Nobody accused their previous nursing home of neglect, but they made it clear that the wounds were already there when they arrived. They had developed in the first four months of the Covid shutdown when my sister, her chief attorney, was not allowed to visit.

Her bandages changed and her sheets were fresh, Peggy turned on her side. Her eyes were calm and when she fell asleep I could see that she knew who I was.

While she slept, I explored her room to see what remnants of her curious and acquisitive life had been preserved in this institutional space. Her photo album was sticky and the pages crackled with age. I knew a lot of these photos. There she was like a bridesmaid, tall and deeply tanned, her blue eyes shining and holding the hand of our father, who lived not long after this picture was taken. There were photos of us as the five sisters we once were and one of Peggy, who was 10 years older than me and who acted as a surrogate mother when I graduated from high school. There was a photo of the friend who followed her to the end of the world, but to whom she could not commit. There are photos of our New Jersey home, nieces and nephews, green decks and swimming pools, and Peggy on her skis.

They came from a life none of us lived anymore, and they ended around 2005 when my mother sold her house and moved into assisted living, leaving Peggy without a landing for the first time in her life. Her bipolar illness, which she found difficult to manage, began to feed on the life she had built before Alzheimer’s quit the job.

Categories
Health

Alzheimer’s Prediction Might Be Present in Writing Exams

Is it possible to predict who will develop Alzheimer’s disease by looking at writing patterns years before symptoms appear?

According to a new study by IBM researchers, the answer is yes.

And she and others say Alzheimer’s is just the beginning. People with a variety of neurological disorders exhibit different language patterns that investigators believe can serve as early warning signs of their illnesses.

For the Alzheimer’s study, the researchers looked at a group of 80 men and women in their eighties – half had Alzheimer’s and the others didn’t. But seven and a half years earlier, everyone had been cognitively normal.

The men and women participated in the Framingham Heart Study, longstanding federal research that requires regular physical and cognitive testing. As part of it, they took a writing test, before either of them developed Alzheimer’s, that asked subjects to describe a drawing of a boy standing on an unsteady stool, reaching for a cookie jar on a tall shelf while a woman went along with them back to him is unaware of an overcrowded sink.

The researchers examined the subjects’ word usage using an artificial intelligence program that looked for subtle language differences. A group of subjects was identified who repeated their word usage at this earlier point when they were all cognitively normal. These subjects also made mistakes, such as B. incorrectly or improperly capitalizing words and using telegraphic language, that is, language with a simple grammatical structure that lacks subjects and words such as “that”, “is” and “are”.

It turned out that the members of this group were the people who developed Alzheimer’s disease.

The AI ​​program predicted who would get Alzheimer’s disease with 75 percent accuracy. This is evident from results recently published in the Lancet journal EClinicalMedicine.

“We had no prior assumption that using words would reveal anything,” said Ajay Royyuru, vice president of health and life science research at the IBM Thomas J. Watson Research Center in Yorktown Heights, NY, where the AI ​​analysis was conducted.

Alzheimer’s researchers were intrigued, saying it will be important to have simple tests that can warn early that a person can develop the progressive without intervention if there are ways to slow or stop the disease – a goal this is so far difficult to achieve is brain disease.

“What is going on here is very smart,” said Dr. Jason Karlawish, an Alzheimer’s researcher at the University of Pennsylvania. “Can you pull out a signal from a large amount of spoken or written language?”

For years, researchers have been analyzing language and voice changes in people with symptoms of neurological diseases – including Alzheimer’s, ALS, Parkinson’s, frontotemporal dementia, bipolar diseases and schizophrenia.

According to Dr. Michael Weiner, who researches Alzheimer’s disease at the University of California at San Francisco, the IBM report is breaking new ground.

“This is the first report I’ve seen that has included people who are completely normal and have been predicted with some accuracy and who would have problems years later,” he said.

The hope is to expand the Alzheimer’s work to find subtle changes in language use by people who have no obvious symptoms but who will later develop other neurological disorders.

Each neurological disorder results in unique language changes that are likely to occur long before the time of diagnosis, said Dr. Murray Grossman, professor of neurology at the University of Pennsylvania and director of the university’s frontotemporal dementia center.

He has studied speech in patients with a type of behavior called frontotemporal dementia, a disorder caused by progressive loss of nerves in the frontal lobes of the brain. These patients exhibit apathy and a decline in judgment, self-control, and empathy that have proven difficult to quantify objectively.

The language is different, said Dr. Grossman because change can be measured.

At the onset of this disease, the pace of speech of the patients changes, with the pauses seemingly being distributed at random. The use of words is also changing – patients use less abstract words.

These changes are directly related to changes in the frontotemporal parts of the brain, said Dr. Grossman. And they seem to be universal, not just in English.

Dr. Adam Boxer, director of the neuroscience clinical research unit at the University of California at San Francisco, is also studying frontotemporal dementia. His tool is a smartphone app. His subjects are healthy people who have inherited a genetic predisposition to develop the disease. His method is to show the subjects a picture and ask them to take a description of what they see.

“We want to measure changes very early, five to ten years before symptoms appear,” he said.

“The beauty of smartphones,” added Dr. Boxer added, “is that you can do all kinds of things.” Researchers can ask people to talk for a minute about something that happened that day or repeat sounds like tatatatata.

Dr. Boxer said he and others focused on speaking because they wanted tests that were non-invasive and inexpensive.

Dr. Cheryl Corcoran, a psychiatrist at the Icahn School of Medicine at Mount Sinai in New York, hopes that language changes will help predict which adolescents and young adults at high risk for schizophrenia may develop the disease.

Drugs used to treat schizophrenia can help those who will develop the disease, but the challenge is identifying who the patients will be. A quarter of people with occasional symptoms saw them go away, and about a third never developed schizophrenia, even though their occasional symptoms persisted.

Guillermo Cecchi, an IBM researcher who was also involved in recent Alzheimer’s research, studied the speech of 34 patients by Dr. Corcoran in search of a “flight of ideas”, that is, the cases in which patients got off track in different ways when speaking and splitting off ideas. He also searched for “language poverty”, which means the use of simple syntactic structures and short sentences.

In addition, Dr. Cecchi and his colleagues found another small group of 96 patients in Los Angeles, 59 of whom had occasional delusions. The rest were healthy people and those with schizophrenia. He asked these people to tell a story they had just heard and looked for the same tell-tale language patterns.

In both groups, the artificial intelligence program was able to predict with an accuracy of 85 percent which subjects would develop schizophrenia three years later.

“It was a lot of small studies that found the same signals,” said Dr. Corcoran. At that point she said, “We haven’t gotten to the point where we can tell people whether they are at risk or not.”

Dr. Cecchi is encouraged, although he finds the studies are still in their infancy.

“Getting the science right and to scale is a priority for us,” he said. “We should have a lot more samples. There are more than 60 million psychiatric interviews in the US each year, but none of these interviews use the tools we have. “

Categories
Health

Tony Bennett Reveals He Has Alzheimer’s Illness

Bennett, who had a career spanning seven decades, scored his first major success in 1951: “Because of you.” In 1962 he recorded “I Left My Heart in San Francisco” which became his trademark. Long after other pop singers died or faded from the waves, Bennett experienced a revival in popularity: He won a Grammy in 1994 for his album “Tony Bennett: MTV Unplugged”. Since then, he has recorded duets with a number of personalities, including James Taylor, Sting and Amy Winehouse.

In 2014 he recorded an album with Lady Gaga, Tony Bennett & Lady Gaga: Cheek to Cheek, which debuted at # 1 on the Billboard Top 200 Pop and Rock Charts. According to the AARP article, a follow-up album with Lady Gaga will be released this spring, which was recorded between 2018 and early 2020.

Lady Gaga was aware of Bennett’s condition when they recorded their last collaboration, the article says. In documentaries from the sessions, Bennett rarely speaks and offers one-word answers such as “thank you” or “yes”.

But his appetite for everything musical remains robust. According to the magazine, he continues to rehearse a 90-minute set twice a week with longtime pianist Lee Musik – without the interruption that can characterize his speech.

According to the Alzheimer’s Association, more than five million Americans live with Alzheimer’s, including one in ten people age 65 and over. Symptoms can initially include repeating questions, losing in familiar places, or misplacing things, and eventually hallucinations, angry outbursts, and the inability to recognize family and friends or even to communicate. Alzheimer’s is not curable.

Susan Bennett serves as her husband’s caregiver.

“I have my moments and it’s going to be very difficult,” she told the magazine. “It’s not fun to argue with someone who doesn’t understand you.” But she added that they felt happier than many other people living with Alzheimer’s.

Categories
Health

Eli Lilly’s Alzheimer’s Drug Reveals Promise in Small Trial

In a small clinical trial, an experimental Alzheimer’s drug slowed the rate at which patients lost the ability to think and care for themselves, drug maker Eli Lilly announced on Monday.

The results have not been published in any form and have not been fully reviewed by other researchers. If exactly, it will be the first time a positive result has been found in a so-called phase 2 study, said Dr. Lon S. Schneider, Professor of Psychiatry, Neurology, and Gerontology at the University of Southern California.

Other experimental drugs for Alzheimer’s disease were never tested in phase 2 studies, went straight to larger phase 3 studies, or did not produce positive results. The Phase 3 trials themselves repeatedly had disappointing results.

The two-year study included 272 patients with brain scans that suggest Alzheimer’s disease. Her symptoms ranged from mild to moderate.

The drug donanemab, a monoclonal antibody, attaches to a small portion of the hard plaques in the brain, which are made up of a protein, amyloid, that is characteristic of Alzheimer’s disease. The patients received the drug by infusion every four weeks.

Participants who received the drug had a 32 percent slowdown in the rate of decline compared to those who received a placebo. In six to twelve months, plaques were gone and stayed gone, said Dr. Daniel Skovronsky, scientific director of the company. At this point, the patients were no longer receiving any medication for the duration of the study – they were given a placebo instead.

The small study needs to be replicated, noted Dr. Michael Weiner, a leading Alzheimer’s researcher at the University of California at San Francisco. Even so, “this is big news,” he said. “This gives hope to patients and their families.”

Eli Lilly has not released the relevant data needed for a thorough analysis, said Dr. Cutter. For example, the company only provided percentages describing functional decline among participants, not the actual numbers.

The company will provide this data at a subsequent meeting and in an article in a medical journal, said Dr. Skovronsky. Eli Lilly received the results on Friday and had to report them immediately, he said, as the results may affect Lilly’s stock.

Dr. Schneider, who served on an independent data protection and monitoring body for the study, said he was not allowed to disclose more data than the company provided.

The experiment served as a test for the so-called amyloid hypothesis. The idea is that Alzheimer’s is closely related to amyloid buildup in the brain; If amyloid accumulation can be prevented or reversed, the disease can be prevented or cured.

Drug companies have spent billions of dollars testing anti-amyloid drugs to no avail, leading many experts to believe the hypothesis is wrong – or that the only way to treat Alzheimer’s is to start very early, before clinical ones There are signs of illness.

The Eli Lilly study recruited patients who were not based on symptoms but rather on scans that showed significant buildups of amyloid in their brain. The researchers also looked at a protein, tau, that forms spaghetti-like tangles in the brain after the disease begins.

“We needed mild to moderate entanglement pathology, but not so many entanglements that the disease may no longer be hoped for,” said Dr. Skovronsky.

The primary endpoint or aim of the study was a measurement that combined performance on mental reasoning and memory tests with ratings of participants’ performance in activities of daily living such as dressing and meal preparation.

The main side effect has been seen regularly in patients given experimental monoclonal antibodies to treat Alzheimer’s disease: an accumulation of fluid in the brain. It occurred in nearly 30 percent of patients, said Dr. Skovronsky, but most of them had no symptoms. The effect was seen on brain scans.

During the study, Eli Lilly started a second phase 2 study, Trailblazer 2, in the hope that the initial efforts would produce results. These results are expected in 2023.

Dr. Skovronsky said Eli Lilly will speak to the Food and Drug Administration and regulators in other countries about giving patients access to the drug.

“Sure, the dates are exciting,” he said. “But we have to see what the regulators say.”

For 25 years he has hoped for definitive evidence that the amyloid hypothesis is correct.

“This is what we’ve been waiting for,” said Dr. Skovronsky.

Categories
Health

Alzheimer’s Researchers Examine a Uncommon Mind

While they waited for Aliria’s body to arrive, Dr. Villegas and the staff each other their demands with: freezers checked, sterile gloves, iodine, cell culture medium, tissue preservative mixed and done. The brain bank frequently sends tissue to its staff overseas, and within a few days samples from Aliria’s brain are being examined in Germany and California, as well as Medellín.

Every brain donation does not begin in a hospital morgue, but in a large and well-stocked funeral home. The arrangement allows researchers to remove the brain and quickly take it one block away to their dissection laboratory, after which the family can proceed with a funeral or cremation.

Aliria’s autopsy began at 11:30 a.m. three hours after her death. The senior team members of Dr. Villegas, Dr. Aguillon and Johana Gómez, a biologist dressed in plastic overalls, masks and face shields, took precautions required by the pandemic while a medical student, Carlos Rueda, took notes.

The team removed the brain relatively easily, though the process is always complicated, with connective tissue that needs to be carefully severed. Dr. Villegas then extracted the pituitary gland and olfactory membrane, structures of interest to Alzheimer’s researchers, from deep within the skull. The group took samples of skin, tumor, and vital organs before leaving the remains of their famous patient, on whom so much research hopes were tied, for cremation.

Within minutes, the group came together again in the Brain Bank Dissection Lab, a room no bigger than a walk-in closet, down the street. It was almost 1 p.m. and Dr. Aguillon put Aliria’s brain on a scale. It weighed 894 grams, just under two pounds – significantly less than a healthy brain. Mr. Rueda started photographing it on a rotating platform, on which a three-dimensional image was created, while Dr. Villegas told and Dr. Aguillon typed.